In 2018, the BioPharma business generated revenues of approximately $3 billion. The unit is a provider of instruments, consumables and software that support the research, discovery, process development and manufacturing workflows of biopharmaceutical drugs.  The business comprises process chromatography hardware and consumables, cell culture media, single-use technologies, development instrumentation and consumables and service.

Upon completion of the sale, the GE Biopharma business will be established as a stand-alone operating company within Danaher's $6.5-billion Life Sciences segment, joining the company's Pall, Beckman Coulter Life Sciences, SCIEX, Leica Microsystems, Molecular Devices, Phenomenex and IDT businesses.

GE's Culp says of the deal, “Today's transaction is a pivotal milestone. It demonstrates that we are executing on our strategy by taking thoughtful and deliberate action to reduce leverage and strengthen our balance sheet.”

GE's Pharmaceutical Diagnostics, currently part of GE Life Sciences, will remain within the GE Healthcare portfolio, the company stated. That business supplies contrast media and molecular imaging consumables for radiology customers worldwide.

Earlier this month, GE announced it was scaling back its much-heralded new corporate headquarters project in the Seaport District of Boston.

Danaher's president and CEO Thomas P. Joyce, Jr., says, “”We expect GE Biopharma to advance our growth and innovation strategy in an important and highly attractive life science market. We see meaningful opportunities to harness the power of the Danaher Business System to further provide GE Biopharma's customers with end-to-end bioprocessing solutions that help enable breakthrough development and production capabilities.”

Danaher, which is a global science and technology firm, expects to finance the all-cash transaction with approximately $3 billion of proceeds from an equity offering from available cash on hand and proceeds from the issuance of debt and/or new credit facilities. Based on the anticipated tax benefits from the transaction structure, Danaher calculates the net purchase price of the deal at approximately $20 billion.

The company expects GE Biopharma to generate revenue of approximately $3.2 billion in 2019, with approximately 75% of those revenues considered recurring.

Danaher estimates the acquisition will reduce GAAP diluted net earnings per share by approximately $1.15 to $1.20, but will be accretive to non-GAAP, adjusted diluted net earnings per share by approximately $0.45 to $0.50 in the first full year post acquisition.

PJT Partners LP, J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and Goldman Sachs acted as financial advisors and Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as legal advisor to GE on the transaction.

Join the 17th Annual GlobeSt Net Lease Conference (formerly a RealShare event) on April 3 & 4 in NYC alongside the industry's most influential and knowledgeable real estate executives from the net lease sector. Click here to register and view the agenda.

Join the GlobeSt.com Women of Influence 2019 conference July 10^th and 11^th in Broomfield, CO, which celebrates the women who drive the commercial real estate industry forward. The event will address the critical role of women in the CRE business. Click here to register and view the agenda.